thank December the second quarter, our and shareholders our we the for year for you XXXX. of Amy, to all as quarter Thanks, results joining us review today fiscal of
recovery business the to patient as We and externalities. results three global devices, the impacts. maximum flow On, chain have peaks; repair at ongoing quarter ResMed of and replace second our the peaks respiratory volumes X,XXX across the of achieved we the markets navigate sleep the double-digit of steady demonstrate of high COVID-XX major their actually of as constraints, months more products. growth continue performance supply and our is COVID extremely two, post impacted benefiting were the well recovery further we incredible from our their components; for countries ResMedians of and as for proud Our in the strong electronic serving business, demand XXX from three, that has devices XX associated this duration almost least very extended of competitor in a demand I'm recall process. that terms The in bottom unlimited patients in of worldwide. line particularly with care demand
the environment are of the healthcare deliver and and into industries teams global remains solutions home its ultimately need systems, finding are Our to patients challenging ways hands to care across we very chain impact. providers, global and supply immune most. Clearly, multiple who products them to physicians not and
we the double-digits in During quarter, year-on-year, market. the meet all were despite the demand able to growing available not
And to We specifically, even chips. forced are being our components our and semiconductor components are suppliers, outbound being more to products allocate thus electronic allocated particularly from we our customers.
an production clear patients with the established to that process of of acuity guiding principles have allocation We first. meet to and priority delivery needs highest devices the give the
ability our the products the supply centers air delivery on for demand impacting we board ultimate our inbound our like from the In rapidly would ongoing addition products. to freight challenges ResMed sea freight respond components costs to component and and and issues, distribution to of are on across increasing Freight as outbound suppliers are to as for to customers.
in the implemented customers. of share we a costs, January products some burden on costs increased these of result starting of with these increased to surcharge our a As
industries products the and world, across necessity increase special of accepted to surcharge around multiple – customers. by all specialty in commodities this prices understood Given has the the from been our
production can partners, critical doing increase to devices. components of of to global need that everything that to our with access closely the additional we working are gain chain we our further We medical supply supply
validating situation parts, the designs, all this the patient. and demand. re-engineering a accelerating also health understand care We of medical development difficult up catch suppliers that We with is the product important and for pieces, most physicians, systems and customer, to are payers, providers, new our further launch new including equipment home customers,
patients, that out-of-hospital number other Our priority our chronic to person's globally. sleep the world's business, COPD, health doing we're and solutions. well we apnea, going grow will from And as world-leading software to who out-of-hospital can diseases, who one are. benefit care those suffer our best therapy they wherever and care leading care software those asthma will to from scaled empower always be respiratory sleep design solutions and each differentiate and To help respiratory deliver as develop, our deliver health be solutions
care to is when that the it need, every they and that goal need they ensure need gets they person it. where Our
step countries broad ongoing in me we discuss market back steady of Let across the that industry. our to in. demand seeing conditions the recovery We're operate
XXX% of XXX% the pre-COVID as pre-COVID patient about has Each a each with and time. We impact. established and for of vaccines in variants diagnosis, monitoring, globally. will processes levels But COVID most at from as sleep in out and solutions an screening, the in flow variant and to protocols and to are a remote towards patient expect still setup, These of adoption we new new health patient absolute COVID increase beyond seeing impact levels to steadily and well-established diminish the divergence well labs, levels digital in few of for XX% cleaning remote locations. countries, roll as metrics impact total pre-COVID continue boosters
governments, local training for providers care as Our global health systems, important home transition ventilators, care needed. and as to ResMed and hospitals, supply masks, working remains and as to team acute committed the care, and state, health with national, well city
disease the of decreasing steadily with severity the consistent Given pre-COVID is impact ventilators now for on and severe hospitalizations each demand the from COVID, levels.
two deliver especially digital medical health asthma as that to update you care three US generation to leading COPD, additional number has our demand for launch Number scaled is well our now very globally. to platform best to provided develop, priorities. much outside continues apnea, in strategic go can platform world's supply needed one as businesses. is for as and differentiate solutions grow me the devices. well. device top sleep devices, next and Number The is XX hospital, Let on delivered the be ResMed solutions new face and This high called our of And design, core and product three AirSense world innovate home. grow software all-time the we and
introduce We the CPAP, total XX APAP platform and leading of globally countries to platform throughout additional In continue available sell AirSense XX [ph] year volume bilevels for maximize sale. to market XXXX. into our expect calendar will parallel, we available to AirSense the
the fact, XX to In the AirSense is inferior only AirSense product XX. is that the
digit quarter, As AirSense the growth you ongoing XX both AirSense platforms XX strong. the results, in of double adoption saw very our remains and this with very,
our we their AirSense are in engaging digital never XX digitally and health patients the industry. platform technology before like therapy the in ecosystem, With
our patients digital are they We and more AirView software Brightree lower physicians. patient also use increased making providers. for it equipment solutions, improved and their suite customers and manage health using When costs for physicians customers medical and including full to have efficiencies, our technology we achieve for outcomes of for easier populations solutions, myAir these home efficient their for patients,
software, evidence are pressure in with to over patients. AirSense therapy. positive and We and the reviewed we than ever even higher study myAir before. AirSense XX% latest see On rates have over a airway platform adoption XX, published that with This was combining our greatest peer showing we adherence AirView platform, XX,XXX myAir of software driving
technology. study the a healthcare and before types at outcomes adhered critical patients and relative term the healthcare this greater systems double adherence than where costs more seeing that ResMed had that these reduction efficiency the are of providers rates the CPAP therapy. fully of are We net for strategy. better a French in The patients the and Demonstrating experience, the mortality importantly those scale XXX this myAir to we in a to ResMed to better fact, versus who we software signing long with control. delivers homecare system with with uptake partnership patient XXXX lower study seen In is the industry of not XX% over patient in up Alaska showed components for more a saw demonstrated result patients better engaging therapy in in
aspect sleep adoption health tools apnea the key increasing driving strategy and awareness, sleep long-term has of diagnosis growth home-based including digital of and and is awareness also telehealth our flow health respiratory adoption top Another funnel. advanced apnea hygiene, acceptance of the but of acceptance through COVID-XX the patients tests. of and respiratory
opportunity. short increasing and important we we're as term that demand long-term in gen term a always demand on focused giving ongoing is Although the focus long recall, not competitor have immediate the
effective and our We customers are management. an apnea treatment diagnostics, create approach identification, sleep even efficient innovating screening, patient partners and to to and more with
technology in We enables will invest end patients. seamless that to an digital continue end experience to for
well during our worldwide. believe call, leading a awareness. physicians, testing help sleep quarter, increase rates as diagnostic in apnea connected Ectosense’s apnea provider technology well we as as sleep can and home cloud can mentioned lab and sleep solutions October in and the digital acquired to of we both hands We general rights As second diagnostic technicians, consumers the significantly use as easy screening of help significantly screening both Ectosense, increase
and chronic serve turn now obstructive business, to patients disease focusing million on our COPD respiratory the patients worldwide our discussion care from suffer the XXX me that asthma million better of to Let with strategy or pulmonary a XXX worldwide.
standard therapeutic pharmaceutical life goal first. with markets technology strong such these This allocation is solutions of in as to ventilation, support we systems risk Adoption of and respiratory high the newer enhance to increasingly ago by patients solid, for Lumis little and highest connected our to guiding AirView noninvasive pandemic. software solution platform Europe including regions where support during our COVID-XX life by care the high where US solutions proactive risk a the they manufacturing to areas, levels help technology a as priority helping We of launched issues and ventilation medical that Demand of reach throughout the early and through devices, to the that highest solutions, world for year severe delivery patients of way was to Propeller to ventilation outside patients the an provided our is this operate sleep at apnea physicians care life world ventilation also of see needs principles we around Our our acuity AirView acuity used flow offerings, as see standard most now of such platform basis the intervention where care give value shifted expand reduce ventilation COPD, care including namely, has meet of core ventilation AirView cloud We called is AirView support the to support for respiratory patients. is continue and on But to is with it our in treatment. hospitalization. first ventilation ongoing millions especially the of ventilation sign a quality and HFT. noninvasive hundreds a manage sleep in that remains well product highest for quarter, from ventilation for the aligned the core world. therapy process, and our the of health care focus over as being noninvasive apnea providers the demand
as a service now care. out-of-hospital business Let software our me for review
based Omicron pandemic customers in data challenging some and facilities The and business, for as the home these grow our is growth equipment increase particularly of utilization and well The settings. home business verticals quarter, based medical home our skilled across as our remains with for During patient business facilities in as as ReSupply. of they home as and the SaaS software including has optimize and showed for highly care, high of our equipment growth. volumes of of the patient SaaS markets SaaS effects growth our variant single year-on-year continue nursing health care and medical tailwinds SNAP including remains products COVID-XX contagious our achieved improve headwind care we been as and to providing well to and improved portfolio a hospice based digit settings. their home sequential We the efficiencies solutions Brightree continued
as COVID latest We then will and many around with the the decline in as regions country happened has this around world. watch this closely and continue peak rates variant to
new for our improve As and to to we existing customer solutions opportunities of COVID pent-up our ease us customers sight demand to continue to restrictions conditions, which more their sell provides better to more expect services investments, and line and for as customers, as increase pipeline. see well technology to
across care growth to solutions single this at digit sustainable as portfolio we revenue As achieving exit our we settings, group growth expect we to look fiscal of year. high our SaaS accelerate,
to or market goal share growth to market continue our innovate growth, we from to rate beat meet our as As is always, take continue and that competitors.
the leading critical SaaS very out-of-hospital we markets. attractive software strategic solutions a broad We care are across for and of provide provider of set mission
Our issue customer latest one greatest reported number and SaaS across address is base staffing solutions the which challenges. our
customers recognize to solve the challenges and achieve Our solutions their software these help they SaaS this expect both scale to technology for and of with persist help problem services and solutions them efficiency and outcomes. our need
have differentiated and customers value our for created ResMed We our within are well-positioned for SaaS and we business.
pipeline innovative solutions, and as we broader businesses confident across Looking respiratory term our and of SaaS long our portfolio remain of ResMed's our sleep solutions. as the at in care, well strategy
can sustainable most beyond, and and our of X% as growth settings partnerships M&A people hospital cost prevalent revenues, ongoing SaaS face well that other With we in conditions. commercial as match. highest a chronic we tuck-in healthcare support other company forward. tune solutions Our with can at the move in as for of verily up sleep and fundamentally transform R&D acceleration the And we our the solutions as CVS to respiratory investments care treat strategic conditions future scale of well this and combination, these and as out through through chronic set excellence M&A care where have no
positioned means winning with Our the and to obstructive in beyond. we chronic centric markets of patient combined underserved culture vastly physician ResMed − medical continue pulmonary provider unique are centric sleep apnea, that centric disease, and approach asthma our
XXX We health of are cloud market devices and medical transforming nights out-of-hospital in in bedside technology on the medical in the healthcare at XX scale, billion leading worldwide. million digital cloud tables over with data connectable over XX.X countries XXX%
patients, health by providers, unlocking and help payers, de-identified using physicians, We are value systems. data to care entire
have lead capabilities every and data at ML-driven unmatched AI in our a We and operations analytics are invested and is that the we scale this privacy, do or competitors, cloud by increasing day. to
this to health excellent goal XXXX We improve every motivates mission toward Our day. inspiring ResMedians XXX during lives last that progress better in and through quarter. again care million made drives
his then hard Before I their to hand the you. that, in more work, and Q&A. Brett Thank my want express I call for gratitude over to sincere X,XXX once Brett perseverance, to remarks, for than again I'll for times. to over hand dedication you. call we the the to move will unprecedented ongoing, to Brett, group these during With over Sydney, residents and
